Understanding Your Prolactinoma Diagnosis
At a Glance
A prolactinoma is a highly treatable, non-cancerous tumor of the pituitary gland that overproduces the hormone prolactin. Most patients have an excellent long-term outlook and successfully manage the condition with medication, returning to normal hormone levels and a healthy quality of life.
Receiving a diagnosis of a prolactinoma can feel overwhelming, but it is important to know that you are not alone. This is a highly manageable condition, and most people with this diagnosis go on to live full, healthy lives with little to no impact on their long-term functional capacity [1][2].
What is a Prolactinoma?
A prolactinoma is a non-cancerous (benign) tumor of the pituitary gland, a pea-sized organ at the base of your brain that acts as your body’s “master gland” for hormones [3]. It is the most common type of functional pituitary tumor, accounting for approximately 45% to 50% of all pituitary adenomas [4][3].
These tumors are specifically called lactotroph adenomas because they develop from lactotroph cells—the specific cells in your pituitary gland responsible for making the hormone prolactin [4][5].
The Biological Mechanism
In a healthy body, the pituitary gland releases prolactin in carefully controlled amounts, primarily to support lactation (breast milk production) [5]. This release is normally kept in check by a chemical from the brain called dopamine, which acts like a “brake” to stop the cells from making too much hormone [6].
In the case of a prolactinoma:
- Overproduction: The tumor cells begin to produce prolactin uncontrollably, leading to high levels in the blood, a condition called hyperprolactinemia [5][1].
- Loss of Control: The tumor cells often lose their sensitivity to the inhibitory “braking” effect of dopamine, leading to further cell growth and hormone secretion [6].
- Hormonal Imbalance: High prolactin levels can interfere with other hormones, often leading to hypogonadotropic hypogonadism—a state where the body produces lower levels of sex hormones like estrogen or testosterone [7][8].
Frequency and Incidence
Prolactinomas are more common than many people realize. While exact figures can vary by region, population-based studies have shown an annual incidence rate of about 1.6 per 100,000 people [9]. In clinical registries, they represent roughly one-quarter of all diagnosed pituitary growths [10][11].
Long-Term Outlook
The general prognosis for someone diagnosed with a prolactinoma is excellent [1].
- Treatment Success: Most patients respond very well to first-line medications called dopamine agonists, which mimic the body’s natural dopamine to shrink the tumor and lower prolactin levels [12][13].
- Remission: In many cases, hormone levels return to normal, and symptoms disappear [14][8]. Remission can even be permanent for some patients after a period of successful treatment [2].
- Surgical Options: For those who do not respond well to medication, modern surgical techniques are highly effective and carry high success rates in specialized centers [15][2].
- Functional Capacity: Long-term studies show that with proper management, patients typically maintain their usual quality of life, work capacity, and fertility [14][2].
While this diagnosis requires ongoing care and monitoring, it is a condition that medical science understands well and can treat effectively.
Continue Reading
To help you navigate your diagnosis and treatment, we have prepared a comprehensive guide. Please read through the following sections to learn more:
Symptoms & Warning Signs: Recognizing Prolactinoma
Learn the warning signs of a prolactinoma. Understand how high prolactin causes irregular periods, low libido, headaches, vision changes, and bone loss.
Making Sure It's Truly a Prolactinoma (Diagnostic Pitfalls)
Learn about common prolactinoma diagnosis pitfalls. Understand the hook effect, stalk effect, macroprolactin, and how medications affect your prolactin levels.
Micro, Macro, and Giant Prolactinomas: What Size Means for You
Learn the differences between micro, macro, and giant prolactinomas. Understand how tumor size and genetics like MEN1 or AIP affect your treatment options.
Treatment Strategies: Medications vs. Surgery
Compare prolactinoma treatment options to make the right choice for your care. Learn about dopamine agonists like cabergoline versus transsphenoidal surgery.
Life After Diagnosis: Long-Term Monitoring and Medication Withdrawal
Learn about long-term prolactinoma care, including when you can stop taking cabergoline, monitoring heart valves and bone density, and managing scan anxiety.
Common questions in this guide
What is a prolactinoma?
What causes the hormone imbalance with a prolactinoma?
What is the long-term outlook for someone with a prolactinoma?
Can my hormone levels return to normal after starting treatment?
Will I need surgery to treat my prolactinoma?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my current prolactin level, and what is our target goal for this number?
- 2.What are the chances that my hormone levels will return to normal after starting treatment?
- 3.How often will I need follow-up blood tests or MRI scans to monitor the tumor?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (15)
- 1
Management outcomes of prolactinoma: a retrospective study from Southern Iraq.
Alobaidy HF, Alidrisi HA, Reman KA, et al.
Journal of medicine and life 2025; (18(9)):869-877 doi:10.25122/jml-2025-0050.
PMID: 41178903 - 2
The PRolaCT studies - a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma.
Zandbergen IM, Zamanipoor Najafabadi AH, Pelsma ICM, et al.
Trials 2021; (22(1)):653 doi:10.1186/s13063-021-05604-y.
PMID: 34563236 - 3
Ept7, a quantitative trait locus that controls estrogen-induced pituitary lactotroph hyperplasia in rat, is orthologous to a locus in humans that has been associated with numerous cancer types and common diseases.
Dennison KL, Chack AC, Hickman MP, et al.
PloS one 2018; (13(9)):e0204727 doi:10.1371/journal.pone.0204727.
PMID: 30261014 - 4
Modern approach to bone comorbidity in prolactinoma.
Uygur MM, Menotti S, Santoro S, Giustina A
Pituitary 2024; (27(6)):802-812 doi:10.1007/s11102-024-01469-x.
PMID: 39541075 - 5
Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis.
Hoffmann A, Adelmann S, Lohle K, et al.
European journal of pediatrics 2018; (177(1)):125-132 doi:10.1007/s00431-017-3042-5.
PMID: 29168011 - 6
Autocrine actions of prolactin contribute to the regulation of lactotroph function in vivo.
Bernard V, Lamothe S, Beau I, et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2018; (32(9)):4791-4797 doi:10.1096/fj.201701111RR.
PMID: 29596024 - 7
[Refractory pituitary prolactinoma:current treatment status and challenges].
Zhu HJ
Zhonghua yi xue za zhi 2025; (105(41)):3738-3742 doi:10.3760/cma.j.cn112137-20250824-02165.
PMID: 41218889 - 8
Diagnosis, misdiagnosis and management of hyperprolactinemia.
Healy ML, Smith TPP, McKenna TJ
Expert review of endocrinology & metabolism 2006; (1(1)):123-132 doi:10.1586/17446651.1.1.123.
PMID: 30743775 - 9
Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study.
Oh JS, Kim HJ, Hann HJ, et al.
Pituitary 2021; (24(1)):38-47 doi:10.1007/s11102-020-01084-6.
PMID: 32949324 - 10
Spectrum of Pituitary disorders: A retrospective study from Basrah, Iraq.
Mansour AA, Alhamza AHA, Almomin AMSA, et al.
F1000Research 2018; (7()):430 doi:10.12688/f1000research.13632.2.
PMID: 30026929 - 11
Assessment of the initial results of pituitary tumor registry at a tertiary hospital of Iran: 2009-2022.
Mohseni S, Mirdamadi N, Mossavarali S, et al.
Journal of diabetes and metabolic disorders 2024; (23(2)):2143-2149 doi:10.1007/s40200-024-01481-9.
PMID: 39610525 - 12
Successful diagnosis and monitoring of giant prolactinomas: the role of sample dilutions.
Schlegel A, Straseski JA
Laboratory medicine 2025; (56(6)):786-789 doi:10.1093/labmed/lmaf021.
PMID: 40493766 - 13
Management of cystic prolactinomas: a review.
Nakhleh A, Shehadeh N, Hochberg I, et al.
Pituitary 2018; (21(4)):425-430 doi:10.1007/s11102-018-0888-0.
PMID: 29654440 - 14
Increase in Testosterone Levels and Improvement of Clinical Symptoms in Eugonadic men With a Prolactin-secreting Adenoma.
Carlier L, Chanson P, Cazabat L, et al.
Journal of the Endocrine Society 2024; (8(9)):bvae135 doi:10.1210/jendso/bvae135.
PMID: 39109291 - 15
The Changing Treatment Paradigm for Prolactinoma-A Prospective Series of 100 Consecutive Neurosurgical Cases.
van Trigt VR, Bakker LEH, Pelsma ICM, et al.
The Journal of clinical endocrinology and metabolism 2025; (110(6)):e1833-e1844 doi:10.1210/clinem/dgae652.
PMID: 39292628
This page provides general educational information about prolactinoma diagnoses and biology. Always consult your endocrinologist or healthcare provider for medical advice and personalized treatment plans.
Get notified when new evidence is published on Prolactinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.